<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222247</url>
  </required_header>
  <id_info>
    <org_study_id>HL98354-HD36801-ALPS</org_study_id>
    <secondary_id>U10HD021410</secondary_id>
    <secondary_id>U10HD027869</secondary_id>
    <secondary_id>U10HD027917</secondary_id>
    <secondary_id>U10HD053118</secondary_id>
    <secondary_id>U10HD027915</secondary_id>
    <secondary_id>U10HD034116</secondary_id>
    <secondary_id>U10HD034208</secondary_id>
    <secondary_id>U10HD053097</secondary_id>
    <secondary_id>U10HD040500</secondary_id>
    <secondary_id>U10HD040485</secondary_id>
    <secondary_id>U10HD040544</secondary_id>
    <secondary_id>U10HD040545</secondary_id>
    <secondary_id>U10HD040560</secondary_id>
    <secondary_id>U10HD040512</secondary_id>
    <secondary_id>U10HD036801</secondary_id>
    <secondary_id>U01HL098354</secondary_id>
    <secondary_id>U01HL098554</secondary_id>
    <secondary_id>U10HD068268</secondary_id>
    <secondary_id>U10HD068258</secondary_id>
    <secondary_id>U10HD068282</secondary_id>
    <nct_id>NCT01222247</nct_id>
  </id_info>
  <brief_title>Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial</brief_title>
  <acronym>ALPS</acronym>
  <official_title>Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids
      can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU
      admissions and improving short-term outcomes in the late preterm infant. The use of antenatal
      corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior
      to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rate of preterm birth has steadily increased in the United States over the past 10 years.
      This increase is driven in part by the rising rate of late preterm birth, defined as those
      births occurring between 34 and 36 weeks. Late preterm infants experience a higher rate of
      readmission than their term counterparts, and these infants are more likely to suffer
      complications such as respiratory distress, kernicterus, feeding difficulties, and
      hypoglycemia. Late preterm infants also have a higher mortality for all causes when compared
      to term infants. The use of antenatal corticosteroids has been shown to be beneficial in
      women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those
      likely to deliver in the late preterm period. If shown to reduce the need for respiratory
      support and thus to decrease the rate of special care nursery admissions and improve
      short-term outcomes, the public health and economic impact will be considerate.This protocol
      describes a randomized placebo controlled trial to evaluate whether antenatal corticosteroids
      can decrease the rate of neonatal respiratory support, thus decreasing the rate of neonatal
      intensive care unit (NICU) admissions and improving short-term outcomes in the late preterm
      infant.

      Two follow-up studies will be conducted concurrently. The first follow-up study will examine
      if the positive effects of betamethasone on lung function will persist in children at 6 years
      of age of mothers randomized to betamethasone with an expected late preterm delivery.
      Neonatal respiratory morbidity is associated with an increased risk of adverse childhood
      respiratory disease. Thus it is quite plausible that the effect of betamethasone, in reducing
      neonatal morbidity, particularly TTN, will translate into improved respiratory morbidity in
      early childhood.The primary outcome is childhood respiratory disease defined by a composite
      outcome of abnormal pulmonary function test (PFT) measured by spirometry, physician diagnosis
      of asthma, or other respiratory illnesses with medication.

      The second follow-up study will examine whether late preterm antenatal betamethasone
      treatment is associated with long-term neurocognitive functioning, and whether there are any
      long-term consequences of what is believed to be transient neonatal hypoglycemia. Cognitive
      function will be measured by the Differential Ability Scales 2nd Edition (DAS-II) core
      components of the general conceptual ability (GCA) that includes verbal ability, non-verbal
      reasoning ability and spatial ability. The primary outcome is defined as a GCA score of &lt;85
      (1 standard deviation below the mean) at 6 years of age or greater.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal Composite Outcome</measure>
    <time_frame>72 hours of life</time_frame>
    <description>Need for respiratory support: Continuous positive airway pressure (CPAP) or humidified high-flow nasal cannula (HHFNC) for greater than or equal to 2 hours or more in the first 72 hours, or fraction of inspired oxygen (FiO2) greater than or equal to 0.30 for 4 hours or more in the first 72 hours, or mechanical ventilation in the first 72 hours, or Extracorporeal membrane oxygenation (ECMO) Stillbirth, or neonatal death less than 72 hours of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Severe Respiratory Complication,</measure>
    <time_frame>72 hours of life</time_frame>
    <description>A severe respiratory complication was defined as any of the following occurrences within 72 hours after birth: CPAP or high-flow nasal cannula for at least 12 hours, supplemental oxygen with a fraction of inspired oxygen of 0.30 or more for at least 24 hours, mechanical ventilation, stillbirth or neonatal death, or the need for ECMO. Except for the duration of CPAP or high-flow nasal cannula and the duration of a fraction of inspired oxygen of 0.30 or more, the criteria for a severe respiratory complication overlap with those of the primary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonates Needing Immediate Resuscitation After Birth</measure>
    <time_frame>Within the first 30 minutes of birth</time_frame>
    <description>Need for resuscitation after birth: any intervention in the first 30 minutes other than blow-by oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Respiratory Distress Syndrome</measure>
    <time_frame>Delivery</time_frame>
    <description>Respiratory distress defined as the presence of clinical signs of respiratory distress (tachypnea, retractions, flaring, grunting, or cyanosis) with an oxygen requirement and a chest x-ray that shows hypoaeration and reticulogranular infiltrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Transient Tachypnea of the Newborn</measure>
    <time_frame>by 72 hours after delivery</time_frame>
    <description>TTN is defined as signs of respiratory distress, specifically tachypnea, that are resolved by 72 hours of age. TTN may be diagnosed in the absence of a chest X-ray or with a chest X-ray that is normal or shows signs of increased perihilar interstitial markings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Neonatal Apnea</measure>
    <time_frame>72 hours of life</time_frame>
    <description>Neonatal apnea with respiratory pauses of more than 20 seconds duration resulting in bradycardia or oxygen desaturation below baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen</measure>
    <time_frame>28 days of life</time_frame>
    <description>Infants requiring supplemental oxygen of more than 0.21 for the first 28 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonates With Pneumonia</measure>
    <time_frame>by 72 hours of life</time_frame>
    <description>Neonatal pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Needing Surfactant Administration</measure>
    <time_frame>Delivery</time_frame>
    <description>Administration of surfactant for neonatal respiratory treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Outcome Composite</measure>
    <time_frame>72 hours of life</time_frame>
    <description>Transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and apnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Pulmonary Air Leak</measure>
    <time_frame>72 hours post delivery</time_frame>
    <description>Neonatal pulmonary air leak syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Death After 72 Hours of Delivery</measure>
    <time_frame>72 hours after delivery through hospital discharge up to 3 weeks</time_frame>
    <description>Neonatal death after 72 hours of life but before hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Weight in grams at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight Less Than 10th Percentile</measure>
    <time_frame>Delivery</time_frame>
    <description>Neonates whose birth weight is less than the 10th percentile at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Number of neonates delivered at ≤ 34 weeks 6 days, between 35 weeks 0 days and 35 weeks 6 days, between 36 weeks 0 days and 36 weeks 6 days, between 37 weeks 0 days and 38 weeks 6 days, or on or after 39 weeks 0 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Necrotizing Enterocolitic (NEC)</measure>
    <time_frame>Delivery</time_frame>
    <description>Defined as modified Bell Stage 2 or 3. Stage 2: Clinical signs and symptoms with pneumatosis intestinalis on radiographs. Stage 3: Advanced clinical signs and symptoms, pneumatosis, impending or proven intestinal perforation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Neonatal Sepsis</measure>
    <time_frame>Delivery</time_frame>
    <description>Clinical suspicion of systemic infection with a positive blood, cerebral spinal fluid, or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evience of cardiovascular collapse or an X-ray confirming infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Intraventricular Hemorrhage</measure>
    <time_frame>Delivery</time_frame>
    <description>Grade 3 or 4 Intraventricular Hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Morbidity Composite</measure>
    <time_frame>Delivery</time_frame>
    <description>A composite endpoint of morbidities known to be affected by steroid administration will also be evaluated. Specifically, this composite will include RDS, intraventricular hemorrhage (IVH), and NEC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Hypoglycemia</measure>
    <time_frame>Delivery through hospital discharge up to 3 weeks</time_frame>
    <description>Glucose &lt; 40 mg per deciliter (2.2 mmol per liter) at any time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until First Neonatal Feeding</measure>
    <time_frame>Delivery to 36 hours post delivery</time_frame>
    <description>Median length of time from delivery until the first neonatal feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Feeding Difficulty</measure>
    <time_frame>Delivery to 36 hours post delivery</time_frame>
    <description>Inability of the neonate to take all feeds (po), i.e. requiring gavage feeds or IV supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hyperbilirubinemia</measure>
    <time_frame>Delivery</time_frame>
    <description>Peak total bilirubin of at least 15 mg% or the use of phototherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Hypothermia</measure>
    <time_frame>Delivery through discharge up to 3 weeks</time_frame>
    <description>Rectal temperature &lt; 36 C at any time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of NICU or Nursery Stay</measure>
    <time_frame>Delivery through hospital discharge up to 3 weeks</time_frame>
    <description>Includes need for NICU or intermediate care admission and length of stay if admitted. For analysis purposes, death before discharge is assigned maximum rank</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Length of Hospital Stay</measure>
    <time_frame>Duration of hospital stay following delivery up to 2 weeks</time_frame>
    <description>Median length of maternal hospital stay following delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Outcomes (Participant-based)</measure>
    <time_frame>Labor and delivery through 72 hours post partum</time_frame>
    <description>Chorioamnionitis: clinical diagnosis and a body temperature of at least 100.4 degrees F., Endometritis: persistent postpartum temperature greater than 100.4 degrees F with uterine tenderness, cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hours From Randomization to Delivery</measure>
    <time_frame>Randomization through delivery</time_frame>
    <description>Median interval of hours from randomization to delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Length of Maternal Hospital Stay</measure>
    <time_frame>Delivery through hospital discharge</time_frame>
    <description>Median length of maternal hospital stay in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2831</enrollment>
  <condition>Pregnancy</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Pregnancy Outcomes</condition>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.</description>
    <arm_group_label>Betamethasone</arm_group_label>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Singleton Pregnancy. A twin pregnancy reduced to singleton (either spontaneously or
        therapeutically) before 14,0 weeks by project gestational age is acceptable

        Gestational age at randomization between 34,0 weeks and 36,5 weeks confirmed by study
        criteria

        High probability of delivery in the late preterm period (any one of the following):

          -  Membrane rupture as defined by the occurrence of any two of the following: pooling of
             fluid in the vaginal vault, positive Nitrazine test, ferning of vaginal fluid,
             positive AmniSure test; or any one of the following: indigo carmine pooling in the
             vagina after amnioinfustion, visible leakage of amniotic fluid from the cervix

        or

          -  Preterm labor with intact membranes. Preterm labor is defined as at least 6 regular
             uterine contractions in an observation period of no more than 60 minutes and at least
             one of the following: cervix greater than or equal to 3cm dilated or at least 75%
             effaced

        or

          -  Planned delivery by induction of labor or cesarean section in no less than 24 hours
             and no more than 7 days, as deemed necessary by the provider. An induction must be
             scheduled to start by 36,5 weeks at the latest, whereas a cesarean delivery must be
             scheduled by 36,6 weeks at the latest. Therefore the latest gestational age for
             randomization is 36,4 weeks for a planned induction. The planned delivery may be for
             any indication, such as the following: prior myomectomy, prior classical cesarean,
             intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, nonreassuring
             fetal heart rate tracing warranting delivery, abruption, placenta previa

        Exclusion Criteria:

          1. Any prior antenatal corticosteroid course during the pregnancy because of potential
             contamination of the placebo group

          2. Candidate for stress dose corticosteroids because of chronic steroid therapy to
             prevent suppression of adrenal gland, because of potential contamination of the
             placebo group

          3. Twin gestation reduced to a singleton gestation at or after 14 weeks 0 days by project
             gestational age either spontaneously or therapeutically

          4. Fetal demise, or known major fetal anomaly, including cardiac anomaly and hydrops

          5. Maternal contraindication to betamethasone: hypersensitivity reaction to any
             components of the medication, idiopathic thromboycytopenic purpura, systemal fungal
             infection in case of exacerbation by betamethasone, use of amphotericin B due to the
             possibility of heart failure with concomitant betamethasone

          6. Pre-gestational diabetes - exclude if the patient was on medication (insulin,
             glyburide) prior to pregnancy

          7. Delivery expected within 12 hours of randomization, because of insufficient time of
             corticosteroids to confer benefit, including any of the following:

             A. Rupture of Membranes (ROM) does not satisfy protocol criteria - exclude if the
             patient being evaluated for Preterm Premature Rupture of Membranes (pPROM), does not
             have preterm labor or planned delivery and does not satisfy the spontaneous membrane
             rupture criteria (any 2 of: positive Nitrazine test, pooling of fluid in the vaginal
             vault test or ferning of vaginal fluid; or indigo carmine pooling in the vagina after
             amnioinfusion; or visible leakage of amniotic fluid from the cervix) B. Rupture of the
             membranes in the presence of more than 6 contractions per hour or cervical dilation of
             3 cm or more, unless oxytocin was withheld for at least 12 hours (other induction
             agents allowed) C. Chorioamnionitis - exclude if patient is diagnosed with
             chorioamnionitis D. Cervical dilation ≥ 8 cm E. Evidence of non-reassuring fetal
             status requiring immediate delivery

          8. Participation in another interventional study that influences neonatal morbidity and
             mortality

          9. Participation in this trial in a previous pregnancy

         10. Delivery at a non-network hospital

         11. At 36, 0 weeks to 36, 5 weeks and quota for 36 weeks already met. To ensure there is
             an adequate proportion of women presenting at 34 to 35 weeks of gestation, enrollment
             will be restricted so that no more than 50% of the women in the trial present at 36
             weeks.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menachem Miodovnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>NICHD Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Clifton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Gyamfi Bannerman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mfmu</url>
    <description>(The public website of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Units (MFMU) Network)</description>
  </link>
  <reference>
    <citation>Davidoff MJ, Dias T, Damus K, Russell R, Bettegowda VR, Dolan S, Schwarz RH, Green NS, Petrini J. Changes in the gestational age distribution among U.S. singleton births: impact on rates of late preterm birth, 1992 to 2002. Semin Perinatol. 2006 Feb;30(1):8-15. Erratum in: Semin Perinatol. 2006 Oct;30(5):313.</citation>
    <PMID>16549207</PMID>
  </reference>
  <reference>
    <citation>Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics. 2006 Sep;118(3):1207-14.</citation>
    <PMID>16951017</PMID>
  </reference>
  <reference>
    <citation>Escobar GJ, Clark RH, Greene JD. Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions. Semin Perinatol. 2006 Feb;30(1):28-33. Review.</citation>
    <PMID>16549211</PMID>
  </reference>
  <reference>
    <citation>Hamilton BE, Ventura SJ, Martin JA, and Sutton PD. Preliminary births for 2004. Health E-stats. Hyattsville, MD: National Center for Health Statistics. Released October 28, 2005.</citation>
  </reference>
  <reference>
    <citation>Buus-Frank ME. The great imposter. Adv Neonatal Care. 2005 Oct;5(5):233-6.</citation>
    <PMID>16202965</PMID>
  </reference>
  <reference>
    <citation>Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B. Annual summary of vital statistics: 2004. Pediatrics. 2006 Jan;117(1):168-83. Erratum in: Pediatrics. 2006 Jun;117(6):2338.</citation>
    <PMID>16396875</PMID>
  </reference>
  <reference>
    <citation>Dudell GG, Jain L. Hypoxic respiratory failure in the late preterm infant. Clin Perinatol. 2006 Dec;33(4):803-30; abstract viii-ix. Review.</citation>
    <PMID>17148006</PMID>
  </reference>
  <reference>
    <citation>Laptook A, Jackson GL. Cold stress and hypoglycemia in the late preterm (&quot;near-term&quot;) infant: impact on nursery of admission. Semin Perinatol. 2006 Feb;30(1):24-7.</citation>
    <PMID>16549210</PMID>
  </reference>
  <reference>
    <citation>Neu J. Gastrointestinal maturation and feeding. Semin Perinatol. 2006 Apr;30(2):77-80. Review.</citation>
    <PMID>16731281</PMID>
  </reference>
  <reference>
    <citation>Bhutani VK, Johnson L. Kernicterus in late preterm infants cared for as term healthy infants. Semin Perinatol. 2006 Apr;30(2):89-97.</citation>
    <PMID>16731283</PMID>
  </reference>
  <reference>
    <citation>Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med. 2008 Jul 17;359(3):262-73. doi: 10.1056/NEJMoa0706475.</citation>
    <PMID>18635431</PMID>
  </reference>
  <reference>
    <citation>McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol. 2008 Jan;111(1):35-41. doi: 10.1097/01.AOG.0000297311.33046.73.</citation>
    <PMID>18165390</PMID>
  </reference>
  <reference>
    <citation>Kramer MS, Demissie K, Yang H, Platt RW, Sauvé R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA. 2000 Aug 16;284(7):843-9.</citation>
    <PMID>10938173</PMID>
  </reference>
  <reference>
    <citation>Gray RF, Indurkhya A, McCormick MC. Prevalence, stability, and predictors of clinically significant behavior problems in low birth weight children at 3, 5, and 8 years of age. Pediatrics. 2004 Sep;114(3):736-43.</citation>
    <PMID>15342847</PMID>
  </reference>
  <reference>
    <citation>Linnet KM, Wisborg K, Agerbo E, Secher NJ, Thomsen PH, Henriksen TB. Gestational age, birth weight, and the risk of hyperkinetic disorder. Arch Dis Child. 2006 Aug;91(8):655-60. Epub 2006 Jun 5.</citation>
    <PMID>16754656</PMID>
  </reference>
  <reference>
    <citation>Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. J Perinatol. 2005 Apr;25(4):251-7.</citation>
    <PMID>15605071</PMID>
  </reference>
  <reference>
    <citation>Stutchfield P, Whitaker R, Russell I; Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ. 2005 Sep 24;331(7518):662. Epub 2005 Aug 22.</citation>
    <PMID>16115831</PMID>
  </reference>
  <reference>
    <citation>Rubaltelli FF, Dani C, Reali MF, Bertini G, Wiechmann L, Tangucci M, Spagnolo A. Acute neonatal respiratory distress in Italy: a one-year prospective study. Italian Group of Neonatal Pneumology. Acta Paediatr. 1998 Dec;87(12):1261-8.</citation>
    <PMID>9894827</PMID>
  </reference>
  <reference>
    <citation>Yoder BA, Gordon MC, Barth WH Jr. Late-preterm birth: does the changing obstetric paradigm alter the epidemiology of respiratory complications? Obstet Gynecol. 2008 Apr;111(4):814-22. doi: 10.1097/AOG.0b013e31816499f4.</citation>
    <PMID>18378739</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Landon MB, Spong CY, Lai Y, Leveno KJ, Varner MW, Moawad AH, Caritis SN, Meis PJ, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai BM, Langer O, Thorp JM, Ramin SM, Mercer BM; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med. 2009 Jan 8;360(2):111-20. doi: 10.1056/NEJMoa0803267.</citation>
    <PMID>19129525</PMID>
  </reference>
  <reference>
    <citation>Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics. 2004 Aug;114(2):372-6.</citation>
    <PMID>15286219</PMID>
  </reference>
  <reference>
    <citation>Shapiro-Mendoza CK, Tomashek KM, Kotelchuck M, Barfield W, Weiss J, Evans S. Risk factors for neonatal morbidity and mortality among &quot;healthy,&quot; late preterm newborns. Semin Perinatol. 2006 Apr;30(2):54-60.</citation>
    <PMID>16731277</PMID>
  </reference>
  <reference>
    <citation>Tomashek KM, Shapiro-Mendoza CK, Weiss J, Kotelchuck M, Barfield W, Evans S, Naninni A, Declercq E. Early discharge among late preterm and term newborns and risk of neonatal morbidity. Semin Perinatol. 2006 Apr;30(2):61-8.</citation>
    <PMID>16731278</PMID>
  </reference>
  <results_reference>
    <citation>Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, Rouse DJ, McKenna DS, Clark EA, Thorp JM Jr, Chien EK, Peaceman AM, Gibbs RS, Swamy GK, Norton ME, Casey BM, Caritis SN, Tolosa JE, Sorokin Y, VanDorsten JP, Jain L; NICHD Maternal–Fetal Medicine Units Network. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016 Apr 7;374(14):1311-20. doi: 10.1056/NEJMoa1516783. Epub 2016 Feb 4.</citation>
    <PMID>26842679</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>December 18, 2018</results_first_submitted>
  <results_first_submitted_qc>January 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Betamethasone</keyword>
  <keyword>Steroids</keyword>
  <keyword>Perinatology</keyword>
  <keyword>Late Preterm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared after completion and publication of the main analyses per NIH policy. Requests can be sent to mfmudatasets@bsc.gwu.edu.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from October 2010 to February 2015 at 17 university-based clinical centers. Women with a singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation and a high probability of delivery in the late preterm period were eligible to be enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Betamethasone</title>
          <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1429"/>
                <participants group_id="P2" count="1402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 2 Doses</title>
              <participants_list>
                <participants group_id="P1" count="860"/>
                <participants group_id="P2" count="826"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="568"/>
                <participants group_id="P2" count="571"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not Receive Assigned Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1427"/>
                <participants group_id="P2" count="1400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Betamethasone</title>
          <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
Betamethasone: The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1429"/>
            <count group_id="B2" value="1402"/>
            <count group_id="B3" value="2831"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean maternal age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="6.3"/>
                    <measurement group_id="B2" value="27.8" spread="6.1"/>
                    <measurement group_id="B3" value="28.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1429"/>
                    <measurement group_id="B2" value="1402"/>
                    <measurement group_id="B3" value="2831"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="381"/>
                    <measurement group_id="B3" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="828"/>
                    <measurement group_id="B2" value="800"/>
                    <measurement group_id="B3" value="1628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, unknown, more than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1429"/>
                    <measurement group_id="B2" value="1402"/>
                    <measurement group_id="B3" value="2831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for trial entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Preterm labor with intact membranes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ruptured membranes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="620"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Exp delivery for gestational HTN or preeclampsia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="385"/>
                    <measurement group_id="B3" value="755"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Expected delivery for fetal growth restriction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Expected delivery for oligohydramnios</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Expected delivery for other indication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at trial entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤34 weeks 6 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="768"/>
                  </measurement_list>
                </category>
                <category>
                  <title>35 weeks 0 days to 35 weeks 6 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                    <measurement group_id="B2" value="532"/>
                    <measurement group_id="B3" value="1103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥36 weeks 0 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="489"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nulliparous</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="448"/>
                    <measurement group_id="B3" value="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preeclampsia or gestational hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="433"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Major congenital anomaly in infant</title>
          <description>Although the presence of a major congenital anomaly was an exclusion criterion, these disorders were not discovered until birth. Therefore we report this as a baseline measure on the publication and not an outcome. To be consistent with the publication, we report this as a baseline measure here.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neonatal Composite Outcome</title>
        <description>Need for respiratory support: Continuous positive airway pressure (CPAP) or humidified high-flow nasal cannula (HHFNC) for greater than or equal to 2 hours or more in the first 72 hours, or fraction of inspired oxygen (FiO2) greater than or equal to 0.30 for 4 hours or more in the first 72 hours, or mechanical ventilation in the first 72 hours, or Extracorporeal membrane oxygenation (ECMO) Stillbirth, or neonatal death less than 72 hours of age</description>
        <time_frame>72 hours of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Composite Outcome</title>
          <description>Need for respiratory support: Continuous positive airway pressure (CPAP) or humidified high-flow nasal cannula (HHFNC) for greater than or equal to 2 hours or more in the first 72 hours, or fraction of inspired oxygen (FiO2) greater than or equal to 0.30 for 4 hours or more in the first 72 hours, or mechanical ventilation in the first 72 hours, or Extracorporeal membrane oxygenation (ECMO) Stillbirth, or neonatal death less than 72 hours of age</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Outcome Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPAP or high-flow cannula ≥2 continuous hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fraction of inspired O2 of ≥0.30 for ≥4 cont hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extracorporeal membrane oxygenation (ECMO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stillbirth or neonatal death ≤72 hr after birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Primary Outcome composite</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for CPAP or high-flow nasal cannula</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Fraction of inspired oxygen</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for mechanical ventilation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Severe Respiratory Complication,</title>
        <description>A severe respiratory complication was defined as any of the following occurrences within 72 hours after birth: CPAP or high-flow nasal cannula for at least 12 hours, supplemental oxygen with a fraction of inspired oxygen of 0.30 or more for at least 24 hours, mechanical ventilation, stillbirth or neonatal death, or the need for ECMO. Except for the duration of CPAP or high-flow nasal cannula and the duration of a fraction of inspired oxygen of 0.30 or more, the criteria for a severe respiratory complication overlap with those of the primary outcome.</description>
        <time_frame>72 hours of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Severe Respiratory Complication,</title>
          <description>A severe respiratory complication was defined as any of the following occurrences within 72 hours after birth: CPAP or high-flow nasal cannula for at least 12 hours, supplemental oxygen with a fraction of inspired oxygen of 0.30 or more for at least 24 hours, mechanical ventilation, stillbirth or neonatal death, or the need for ECMO. Except for the duration of CPAP or high-flow nasal cannula and the duration of a fraction of inspired oxygen of 0.30 or more, the criteria for a severe respiratory complication overlap with those of the primary outcome.</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe Respiratory Complication Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPAP or high-flow cannula ≥12 continuous hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fraction of inspired 02 of ≥0.30 for ≥24 cont hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonates Needing Immediate Resuscitation After Birth</title>
        <description>Need for resuscitation after birth: any intervention in the first 30 minutes other than blow-by oxygen</description>
        <time_frame>Within the first 30 minutes of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonates Needing Immediate Resuscitation After Birth</title>
          <description>Need for resuscitation after birth: any intervention in the first 30 minutes other than blow-by oxygen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1422"/>
                <count group_id="O2" value="1390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Respiratory Distress Syndrome</title>
        <description>Respiratory distress defined as the presence of clinical signs of respiratory distress (tachypnea, retractions, flaring, grunting, or cyanosis) with an oxygen requirement and a chest x-ray that shows hypoaeration and reticulogranular infiltrates</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Respiratory Distress Syndrome</title>
          <description>Respiratory distress defined as the presence of clinical signs of respiratory distress (tachypnea, retractions, flaring, grunting, or cyanosis) with an oxygen requirement and a chest x-ray that shows hypoaeration and reticulogranular infiltrates</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Transient Tachypnea of the Newborn</title>
        <description>TTN is defined as signs of respiratory distress, specifically tachypnea, that are resolved by 72 hours of age. TTN may be diagnosed in the absence of a chest X-ray or with a chest X-ray that is normal or shows signs of increased perihilar interstitial markings</description>
        <time_frame>by 72 hours after delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Transient Tachypnea of the Newborn</title>
          <description>TTN is defined as signs of respiratory distress, specifically tachypnea, that are resolved by 72 hours of age. TTN may be diagnosed in the absence of a chest X-ray or with a chest X-ray that is normal or shows signs of increased perihilar interstitial markings</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Neonatal Apnea</title>
        <description>Neonatal apnea with respiratory pauses of more than 20 seconds duration resulting in bradycardia or oxygen desaturation below baseline.</description>
        <time_frame>72 hours of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neonatal Apnea</title>
          <description>Neonatal apnea with respiratory pauses of more than 20 seconds duration resulting in bradycardia or oxygen desaturation below baseline.</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen</title>
        <description>Infants requiring supplemental oxygen of more than 0.21 for the first 28 days of life</description>
        <time_frame>28 days of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen</title>
          <description>Infants requiring supplemental oxygen of more than 0.21 for the first 28 days of life</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonates With Pneumonia</title>
        <description>Neonatal pneumonia</description>
        <time_frame>by 72 hours of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonates With Pneumonia</title>
          <description>Neonatal pneumonia</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Needing Surfactant Administration</title>
        <description>Administration of surfactant for neonatal respiratory treatment</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Needing Surfactant Administration</title>
          <description>Administration of surfactant for neonatal respiratory treatment</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Outcome Composite</title>
        <description>Transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and apnea</description>
        <time_frame>72 hours of life</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Outcome Composite</title>
          <description>Transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and apnea</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Pulmonary Air Leak</title>
        <description>Neonatal pulmonary air leak syndrome</description>
        <time_frame>72 hours post delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Pulmonary Air Leak</title>
          <description>Neonatal pulmonary air leak syndrome</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Death After 72 Hours of Delivery</title>
        <description>Neonatal death after 72 hours of life but before hospital discharge.</description>
        <time_frame>72 hours after delivery through hospital discharge up to 3 weeks</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Death After 72 Hours of Delivery</title>
          <description>Neonatal death after 72 hours of life but before hospital discharge.</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight</title>
        <description>Weight in grams at delivery</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight</title>
          <description>Weight in grams at delivery</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2637" spread="480"/>
                    <measurement group_id="O2" value="2654" spread="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight Less Than 10th Percentile</title>
        <description>Neonates whose birth weight is less than the 10th percentile at delivery</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight Less Than 10th Percentile</title>
          <description>Neonates whose birth weight is less than the 10th percentile at delivery</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <description>Number of neonates delivered at ≤ 34 weeks 6 days, between 35 weeks 0 days and 35 weeks 6 days, between 36 weeks 0 days and 36 weeks 6 days, between 37 weeks 0 days and 38 weeks 6 days, or on or after 39 weeks 0 days</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <description>Number of neonates delivered at ≤ 34 weeks 6 days, between 35 weeks 0 days and 35 weeks 6 days, between 36 weeks 0 days and 36 weeks 6 days, between 37 weeks 0 days and 38 weeks 6 days, or on or after 39 weeks 0 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤34 weeks 6 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 weeks 0 days to 35 weeks 6 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                    <measurement group_id="O2" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks 0 days to 36 weeks 6 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609"/>
                    <measurement group_id="O2" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>37 weeks 0 days to 38 weeks 6 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥39 weeks 0 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Necrotizing Enterocolitic (NEC)</title>
        <description>Defined as modified Bell Stage 2 or 3. Stage 2: Clinical signs and symptoms with pneumatosis intestinalis on radiographs. Stage 3: Advanced clinical signs and symptoms, pneumatosis, impending or proven intestinal perforation.</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Necrotizing Enterocolitic (NEC)</title>
          <description>Defined as modified Bell Stage 2 or 3. Stage 2: Clinical signs and symptoms with pneumatosis intestinalis on radiographs. Stage 3: Advanced clinical signs and symptoms, pneumatosis, impending or proven intestinal perforation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Neonatal Sepsis</title>
        <description>Clinical suspicion of systemic infection with a positive blood, cerebral spinal fluid, or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evience of cardiovascular collapse or an X-ray confirming infection.</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neonatal Sepsis</title>
          <description>Clinical suspicion of systemic infection with a positive blood, cerebral spinal fluid, or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evience of cardiovascular collapse or an X-ray confirming infection.</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Intraventricular Hemorrhage</title>
        <description>Grade 3 or 4 Intraventricular Hemorrhage</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Intraventricular Hemorrhage</title>
          <description>Grade 3 or 4 Intraventricular Hemorrhage</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Morbidity Composite</title>
        <description>A composite endpoint of morbidities known to be affected by steroid administration will also be evaluated. Specifically, this composite will include RDS, intraventricular hemorrhage (IVH), and NEC</description>
        <time_frame>Delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Morbidity Composite</title>
          <description>A composite endpoint of morbidities known to be affected by steroid administration will also be evaluated. Specifically, this composite will include RDS, intraventricular hemorrhage (IVH), and NEC</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Hypoglycemia</title>
        <description>Glucose &lt; 40 mg per deciliter (2.2 mmol per liter) at any time</description>
        <time_frame>Delivery through hospital discharge up to 3 weeks</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Hypoglycemia</title>
          <description>Glucose &lt; 40 mg per deciliter (2.2 mmol per liter) at any time</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Until First Neonatal Feeding</title>
        <description>Median length of time from delivery until the first neonatal feeding</description>
        <time_frame>Delivery to 36 hours post delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until First Neonatal Feeding</title>
          <description>Median length of time from delivery until the first neonatal feeding</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="1.4" upper_limit="24.7"/>
                    <measurement group_id="O2" value="9.9" lower_limit="1.7" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Feeding Difficulty</title>
        <description>Inability of the neonate to take all feeds (po), i.e. requiring gavage feeds or IV supplementation.</description>
        <time_frame>Delivery to 36 hours post delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Feeding Difficulty</title>
          <description>Inability of the neonate to take all feeds (po), i.e. requiring gavage feeds or IV supplementation.</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hyperbilirubinemia</title>
        <description>Peak total bilirubin of at least 15 mg% or the use of phototherapy.</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hyperbilirubinemia</title>
          <description>Peak total bilirubin of at least 15 mg% or the use of phototherapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Hypothermia</title>
        <description>Rectal temperature &lt; 36 C at any time</description>
        <time_frame>Delivery through discharge up to 3 weeks</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Hypothermia</title>
          <description>Rectal temperature &lt; 36 C at any time</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of NICU or Nursery Stay</title>
        <description>Includes need for NICU or intermediate care admission and length of stay if admitted. For analysis purposes, death before discharge is assigned maximum rank</description>
        <time_frame>Delivery through hospital discharge up to 3 weeks</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of NICU or Nursery Stay</title>
          <description>Includes need for NICU or intermediate care admission and length of stay if admitted. For analysis purposes, death before discharge is assigned maximum rank</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NICU stay of any duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596"/>
                    <measurement group_id="O2" value="629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NICU stay of ≥3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470"/>
                    <measurement group_id="O2" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for NICU stay of any duration</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for duration greater than or equal to 3 days</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Length of Hospital Stay</title>
        <description>Median length of maternal hospital stay following delivery</description>
        <time_frame>Duration of hospital stay following delivery up to 2 weeks</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Length of Hospital Stay</title>
          <description>Median length of maternal hospital stay following delivery</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Outcomes (Participant-based)</title>
        <description>Chorioamnionitis: clinical diagnosis and a body temperature of at least 100.4 degrees F., Endometritis: persistent postpartum temperature greater than 100.4 degrees F with uterine tenderness, cesarean delivery</description>
        <time_frame>Labor and delivery through 72 hours post partum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcomes (Participant-based)</title>
          <description>Chorioamnionitis: clinical diagnosis and a body temperature of at least 100.4 degrees F., Endometritis: persistent postpartum temperature greater than 100.4 degrees F with uterine tenderness, cesarean delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chorioamnionitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum Endometritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cesarean Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for chorioamnionitis</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Postpartum Endometritis</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for cesarean delivery</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hours From Randomization to Delivery</title>
        <description>Median interval of hours from randomization to delivery</description>
        <time_frame>Randomization through delivery</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Hours From Randomization to Delivery</title>
          <description>Median interval of hours from randomization to delivery</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="15.2" upper_limit="111.6"/>
                    <measurement group_id="O2" value="30.6" lower_limit="14.6" upper_limit="111.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for interval from randomization to delivery</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Length of Maternal Hospital Stay</title>
        <description>Median length of maternal hospital stay in days</description>
        <time_frame>Delivery through hospital discharge</time_frame>
        <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
        <group_list>
          <group group_id="O1">
            <title>Betamethasone</title>
            <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Length of Maternal Hospital Stay</title>
          <description>Median length of maternal hospital stay in days</description>
          <population>The number of participants analyzed accounts for the 4 participants for which baseline measures were obtained but who were subsequently lost to follow-up (2 in each group).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1427"/>
                <count group_id="O2" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of randomization into the study through 72 hours after delivery.</time_frame>
      <desc>Adverse events were documented by research nurse coordinators and principal investigators on standardized study protocol forms and reported to the study sponsor. Non-serious adverse events are reported for patients who received 1 or 2 doses of drug or placebo. Not all participants who were randomized received a study injection.</desc>
      <group_list>
        <group group_id="E1">
          <title>Betamethasone</title>
          <description>A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1402"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection type 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1402"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructed bowel</sub_title>
                <description>Maternal obstructed bowel</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal death</sub_title>
                <description>Two infants died after 72 hours of life but before hospital discharge.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar plexus stretch injury</sub_title>
                <description>Maternal stretch injury</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Postpartum Hemorrhage</sub_title>
                <description>Postpartum Hemorrhage</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1402"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Postpartum pregnancy complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1402"/>
              </event>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <description>Pregnancy complication</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1402"/>
              </event>
              <event>
                <sub_title>Delayed pre-eclampsia</sub_title>
                <description>Pregnancy complication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Low blood pressure</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="223" subjects_at_risk="1428"/>
                <counts group_id="E2" subjects_affected="352" subjects_at_risk="1397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin reaction at injecton site</sub_title>
                <description>Pain, bruising, swelling or other local reaction at the injection site with first and/or second dose</description>
                <counts group_id="E1" events="223" subjects_affected="223" subjects_at_risk="1428"/>
                <counts group_id="E2" events="352" subjects_affected="352" subjects_at_risk="1397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Thom, Ph.D.</name_or_title>
      <organization>The George Washington University Biostatistics Center</organization>
      <phone>301-881-9260</phone>
      <email>e_thom@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

